- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Momelotinib: an emerging treatment for myelofibrosis patients with anemia ; volume:15 ; number:1 ; day:19 ; month:1 ; year:2022 ; pages:1-17 ; date:12.2022
Journal of hematology & oncology ; 15, Heft 1 (19.1.2022), 1-17, 12.2022
- Creator
-
Chifotides, Helen T.
Bose, Prithviraj
Verstovsek, Srdan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-021-01157-4
- URN
-
urn:nbn:de:101:1-2022061719563222510599
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chifotides, Helen T.
- Bose, Prithviraj
- Verstovsek, Srdan
- SpringerLink (Online service)
Other Objects (12)
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
How I manage anemia related to myelofibrosis and its treatment regimens
Myelofibrosis Treatment Algorithm 2018
Prefibrotic myelofibrosis: treatment algorithm 2018
Myelofibrosis treatment history and future prospects
Myelofibrosis
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat
Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?
Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
How I manage anemia related to myelofibrosis and its treatment regimens
Myelofibrosis Treatment Algorithm 2018
Prefibrotic myelofibrosis: treatment algorithm 2018
Myelofibrosis treatment history and future prospects
Myelofibrosis
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat
Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?
Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
How I manage anemia related to myelofibrosis and its treatment regimens
Myelofibrosis Treatment Algorithm 2018
Prefibrotic myelofibrosis: treatment algorithm 2018
Myelofibrosis treatment history and future prospects
Myelofibrosis
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat
Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
Is Treatment for Cytopenic Myelofibrosis Still an Unmet Clinical Need?
Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients